• Je něco špatně v tomto záznamu ?

Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study

A. Balduzzi, JH. Dalle, J. Wachowiak, I. Yaniv, A. Yesilipek, P. Sedlacek, M. Bierings, M. Ifversen, S. Sufliarska, K. Kalwak, A. Lankester, J. Toporski, L. Di Maio, E. Glogova, U. Poetschger, C. Peters,

. 2019 ; 25 (11) : 2197-2210. [pub] 20190715

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20025521

Eligibility criteria for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia (ALL) vary according to disease characteristics, response to treatment, and type of available donor. As the risk profile of the patient worsens, a wider degree of HLA mismatching is considered acceptable. A total of 138 children and adolescents who underwent HSCT from HLA-identical sibling donors (MSDs) and 210 who underwent HSCT from matched donors (MDs) (median age, 9 years; 68% male) in 10 countries were enrolled in the International-BFM ALL SCT 2007 prospective study to assess the impact of donor type in HSCT for pediatric ALL. The 4-year event-free survival (65 ± 5% vs 61 ± 4%; P = .287), overall survival (72 ± 4% versus 68 ± 4%; P = .235), cumulative incidence of relapse (24 ± 4% versus 25 ± 3%; P = .658) and nonrelapse mortality (10 ± 3% versus 14 ± 3%; P = .212) were not significantly different between MSD and MD graft recipients. The risk of extensive chronic (cGVHD) was lower in MD graft recipients than in MSD graft recipients (hazard ratio [HR], .38; P = .002), and the risks of severe acute GVHD (aGVHD) and cGVHD were higher in peripheral blood stem cell graft recipients than in bone marrow graft recipients (HR, 2.06; P = .026). Compared with the absence of aGVHD, grade I-II aGVHD was associated with a lower risk of graft failure (HR, .63; P = .042) and grade III-IV aGVHD was associated with a higher risk of graft failure (HR, 1.85; P = .020) and nonleukemic death (HR, 8.76; P < .0001), despite a lower risk of relapse (HR, .32; P = .021). Compared with the absence of cGVHD, extensive cGVHD was associated with a higher risk of nonleukemic death (HR, 8.12; P < .0001). Because the outcomes of transplantation from a matched donor were not inferior to those of transplantation from an HLA-identical sibling, eligibility criteria for transplantation might be reviewed in pediatric ALL and possibly in other malignancies as well. Bone marrow should be the preferred stem cell source, and the addition of MTX should be considered in MSD graft recipients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025521
003      
CZ-PrNML
005      
20201222155235.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bbmt.2019.07.011 $2 doi
035    __
$a (PubMed)31319153
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Balduzzi, Adriana $u Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo, Monza, Italy. Electronic address: abalduzzi@fondazionembbm.it.
245    10
$a Transplantation in Children and Adolescents with Acute Lymphoblastic Leukemia from a Matched Donor versus an HLA-Identical Sibling: Is the Outcome Comparable? Results from the International BFM ALL SCT 2007 Study / $c A. Balduzzi, JH. Dalle, J. Wachowiak, I. Yaniv, A. Yesilipek, P. Sedlacek, M. Bierings, M. Ifversen, S. Sufliarska, K. Kalwak, A. Lankester, J. Toporski, L. Di Maio, E. Glogova, U. Poetschger, C. Peters,
520    9_
$a Eligibility criteria for hematopoietic stem cell transplantation (HSCT) in acute lymphoblastic leukemia (ALL) vary according to disease characteristics, response to treatment, and type of available donor. As the risk profile of the patient worsens, a wider degree of HLA mismatching is considered acceptable. A total of 138 children and adolescents who underwent HSCT from HLA-identical sibling donors (MSDs) and 210 who underwent HSCT from matched donors (MDs) (median age, 9 years; 68% male) in 10 countries were enrolled in the International-BFM ALL SCT 2007 prospective study to assess the impact of donor type in HSCT for pediatric ALL. The 4-year event-free survival (65 ± 5% vs 61 ± 4%; P = .287), overall survival (72 ± 4% versus 68 ± 4%; P = .235), cumulative incidence of relapse (24 ± 4% versus 25 ± 3%; P = .658) and nonrelapse mortality (10 ± 3% versus 14 ± 3%; P = .212) were not significantly different between MSD and MD graft recipients. The risk of extensive chronic (cGVHD) was lower in MD graft recipients than in MSD graft recipients (hazard ratio [HR], .38; P = .002), and the risks of severe acute GVHD (aGVHD) and cGVHD were higher in peripheral blood stem cell graft recipients than in bone marrow graft recipients (HR, 2.06; P = .026). Compared with the absence of aGVHD, grade I-II aGVHD was associated with a lower risk of graft failure (HR, .63; P = .042) and grade III-IV aGVHD was associated with a higher risk of graft failure (HR, 1.85; P = .020) and nonleukemic death (HR, 8.76; P < .0001), despite a lower risk of relapse (HR, .32; P = .021). Compared with the absence of cGVHD, extensive cGVHD was associated with a higher risk of nonleukemic death (HR, 8.12; P < .0001). Because the outcomes of transplantation from a matched donor were not inferior to those of transplantation from an HLA-identical sibling, eligibility criteria for transplantation might be reviewed in pediatric ALL and possibly in other malignancies as well. Bone marrow should be the preferred stem cell source, and the addition of MTX should be considered in MSD graft recipients.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a alografty $7 D064591
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a nemoc štěpu proti hostiteli $x etiologie $x mortalita $7 D006086
650    12
$a HLA antigeny $7 D006680
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a transplantace periferních kmenových buněk $7 D036102
650    12
$a akutní lymfatická leukemie $x mortalita $x terapie $7 D054198
650    _2
$a prospektivní studie $7 D011446
650    _2
$a retrospektivní studie $7 D012189
650    12
$a sourozenci $7 D035781
650    _2
$a míra přežití $7 D015996
650    12
$a nepříbuzný dárce $7 D061349
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dalle, Jean-Hugues $u Hemato-Immunology Department, Robert-Debre Hospital, APHP and Paris-Diderot University, Paris, France.
700    1_
$a Wachowiak, Jacek $u Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland.
700    1_
$a Yaniv, Isaac $u Pediatric Hematology Oncology, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Yesilipek, Akif $u Antalya Medicalpark Hospital, Pediatric Stem Cell Transplantation Unit, Antalya, Turkey.
700    1_
$a Sedlacek, Petr $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic.
700    1_
$a Bierings, Marc $u Princess Maxima Centre for Pediatric Oncology and Utrecht University Children's Hospital, Utrecht, The Netherlands.
700    1_
$a Ifversen, Marianne $u Department of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
700    1_
$a Sufliarska, Sabina $u Bone Marrow Transplantation Unit, Comenius University Children's Hospital, Bratislava, Slovakia, Bratislava, Slovakia.
700    1_
$a Kalwak, Krzysztof $u Department of Pediatric Hematology/Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland.
700    1_
$a Lankester, Arjan $u Department of Pediatrics, University Medical Centre, Willem-Alexander Children's Hospital, Leiden, The Netherlands.
700    1_
$a Toporski, Jacek $u Children's Hospital, Skåne University Hospital, Lund, Sweden.
700    1_
$a Di Maio, Lucia $u Clinica Pediatrica, Università degli Studi di Milano Bicocca, Fondazione Monza e Brianza per il Bambino e la sua Mamma, Ospedale San Gerardo, Monza, Italy.
700    1_
$a Glogova, Evgenia $u St Anna Children's Hospital, UKKJ, MUW, Vienna, Austria.
700    1_
$a Poetschger, Ulrike $u St Anna Children's Hospital, UKKJ, MUW, Vienna, Austria.
700    1_
$a Peters, Christina $u St Anna Children's Hospital, UKKJ, MUW, Vienna, Austria.
773    0_
$w MED00008579 $t Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation $x 1523-6536 $g Roč. 25, č. 11 (2019), s. 2197-2210
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31319153 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201222155231 $b ABA008
999    __
$a ok $b bmc $g 1599666 $s 1116207
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 11 $d 2197-2210 $e 20190715 $i 1523-6536 $m Biology of blood and marrow transplantation $n Biol Blood Marrow Transplant $x MED00008579
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace